AnHeart Therapeutics

Thank you for your interest in AnHeart Therapeutics. We are now a Nuvation Bio company. For the latest news, visit Nuvation Bio. 

We’re pleased to announce that AnHeart is now officially part of Nuvation Bio. We look forward to working together to bring new cancer therapies to patients in need.

We’re excited to announce we’ve entered into an agreement for Nuvation Bio to acquire AnHeart Therapeutics. We look forward to continuing our work as part of Nuvation Bio to bring new cancer therapies to patients in need of better options.   Learn more: https://lnkd.in/emxNUxGF

Today AnHeart and Innovent Biologics announced that China’s National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for our investigational precision therapy as a first-line treatment for adults with advanced or metastatic ROS1-positive NSCLC who have not been previously treated with ROS1 TKIs.     We look forward to continuing to work closely with Innovent and China’s regulatory authority to bring a potential new option to people earlier in their treatment journey.      Learn more: https://lnkd.in/eNVSSzaS     #ROS1 #PrecisionOncology

We had a great #JPM2024 week and hope everyone else did too. We're feeling energized and inspired and are looking forward to a busy 2024 focused on continued progress developing our pipeline of precision oncology medicines.  #JPM24

We’re excited to be attending #JPM2024 in San Francisco! We look forward to connecting with industry leaders and peers to discuss the latest innovations in healthcare. Connect with us onsite to learn more about our pipeline of novel precision therapies for people living with cancer, including our investigational next-generation therapy for ROS1-positive NSCLC. #JPM24

Today, AnHeart and Innovent Biologics announced that our recently accepted NDA in China for our lead investigational precision therapy has been granted Priority Review Designation. This Priority Review Designation further reinforces the urgent need for new options for ROS1-positive NSCLC patients who have been previously treated with ROS1 TKIs in China.    Learn more: https://lnkd.in/ej7Jxv3B #ROS1 #PrecisionOncology

Today we announced an important milestone: a New Drug Application for our lead investigational therapy, taletrectinib, has been accepted in China. This marks AnHeart's first global regulatory submission for taletrectinib, an investigational precision therapy in development for ROS1-positive non-small cell lung cancer. We look forward to working with our partner in China, Innovent, and regulatory authorities to hopefully make taletrectinib available to patients in need as soon as possible. Learn more: https://lnkd.in/e2gxjHRn #ROS1 #lungcancer #precisionmedicine

#InTheNews: On October 31, President Biden officially proclaimed November to be National Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death worldwide, affecting over 650,000 people in the U.S. today. Now, more than ever, we remain committed to delivering on our promise of bringing new targeted treatment options to people living with ROS1-positive non-small cell lung cancer. Learn more: https://lnkd.in/g_NDxheS #LCAM #PrecisionOncology

We are excited to announce the appointment of Guilin H. as SVP of Development and Amy Muse as VP of U.S. Commercial. Guilin and Amy are exceptional leaders, each with more than 20 years of experience in their respective areas of expertise. In their roles, they’ll help advance our oncology pipeline, and bring us a step closer towards our ultimate goal of developing precision therapies for people with cancer who are in need of better options.  Join us in welcoming Guilin and Amy to our team! https://lnkd.in/eQUBTjmr #AnHeart #PrecisionOncology